目的 分析2021-2025年某社区卫生服务中心失眠患者用药趋势，为社区失眠规范化管理提供参考。方法 回顾性收集某社区卫生服务中心2021年1月至2025年12月失眠相关药物处方数据，共纳入处方18,042张，涉及患者3,805人。统计处方量、药物种类、患者年龄、性别、伴随疾病等信息。根据处方次数及平均处方间隔天数将患者分为三类：偶发就诊型（1次）、短期治疗型（2~10次且平均间隔≥60天）和长期用药型（>10次或平均间隔<60天），分析各类患者的用药特征及伴随疾病分布。结果 处方量从2021年2,688张增至2025年5,734张，增长2.1倍，就诊人数增长1.6倍。艾司唑仑占比从66.22%降至41.75%，右佐匹克隆从13.28%升至54.99%，2024年为关键转折点；各年龄组右佐匹克隆使用均呈上升趋势，2025年组间差异趋于消失（48%~61%）。患者平均年龄从73.2岁降至69.5岁（Tukey HSD，P<0.05），≥80岁组占比从29.36%降至14.28%。偶发就诊型占42.6%，短期治疗型占25.9%，长期用药型占31.6%。长期用药型消耗全部处方的68.2%，平均处方间隔37.3 d（中位34 d），右佐匹克隆占比43.2%。高血压是最常见伴随疾病，患病率随年龄升高（28.17%~68.17%）；高血脂和焦虑呈倒U型分布。结论 社区失眠就诊需求快速增长，药物结构向新型非苯二氮?类药物明显转变。失眠患者呈年轻化趋势。长期用药型患者消耗了大部分处方资源，其用药管理模式需结合处方间隔特征进行精准分层，并重视老年患者心血管代谢共病的综合管理。

To analyze the medication trends and characteristics of insomnia patients in a community health service center from 2021 to 2025, and to provide evidence for standardized community-based insomnia management. METHODS A retrospective analysis was conducted on insomnia-related prescription data from a community health service center between January 2021 and December 2025. A total of 18,042 prescriptions involving 3,805 patients were included. Prescription volume, drug types, patient age, sex, and comorbidities were analyzed. Patients were classified into three types based on prescription count and average prescription interval: episodic consultation type (1 prescription), short-term treatment type (2–10 prescriptions with interval ≥60 days), and long-term medication type (>10 prescriptions or interval <60 days). RESULTS Prescriptions increased from 2,688 in 2021 to 5,734 in 2025 (2.1-fold), with a 1.6-fold increase in patient visits. Estazolam decreased from 66.22% to 41.75%, while eszopiclone increased from 13.28% to 54.99%, with 2024 as the turning point. Eszopiclone usage increased across all age groups, converging to 48%–61% by 2025. Mean age decreased from 73.2 to 69.5 years (Tukey HSD, P<0.05), and the proportion of patients aged ≥80 years dropped from 29.36% to 14.28%. Episodic consultation type accounted for 42.6%, short-term treatment type 25.9%, and long-term medication type 31.6%. The long-term type consumed 68.2% of all prescriptions, with an average prescription interval of 37.3 days (median 34 days) and eszopiclone accounting for 43.2%. Hypertension was the most common comorbidity, increasing with age (28.17%–68.17%). Hyperlipidemia and anxiety showed an inverted U-shaped distribution. CONCLUSION Community insomnia treatment demand is growing rapidly, with a significant shift toward newer non-benzodiazepines and a trend toward younger patient demographics. Long-term medication patients consume the majority of prescription resources and require precise stratification based on prescription interval patterns, along with integrated management of cardiometabolic comorbidities in older adults.

目的 分析抽检血液成分关键指标结果并采用趋势分析方法进行评估。方法 收集整理2015—2017年每月1次的8种血液成分质量控制的检测数据,选择关键指标并制作折线图,联合行动限和警戒限进行趋势分析。结果 未能100%达到GB 18469—2012《全血及成分血质量要求》的项目包括悬浮红细胞容量及Hct、单采血小板及浓缩血小板血小板含量、新鲜冰冻血浆及冷沉淀VIII因子含量。新鲜冰冻血浆及冷沉淀的VIII因子含量项目分别出现10次和5次偏离数据;单采血小板及浓缩血小板的血小板含量项目分别出现3次和4次偏离数据。结论 根据血液成分的关键指标结果进行趋势分析发现问题,主动寻找原因并及时采取相应措施,是确保血液质量的一种有效手段。

Objective To analyze and evaluate the results of key indexes of the blood component by trend analysis. Methods Collected and arranged the data of eight kinds of blood component quality control,which was did once month in 2015-2017.Selected the key indexes and made the line charts.Allied with the action limits and warning limits for trend analysis. Results The key indexes could not 100% meet the “Quality requirements for whole blood and component blood”,including capacity and Hct of suspended red blood cell,platelet content of apheresis platelets and platelets concentrate,factor VIII content of fresh frozen plasma and cryoprecipitate.The factor VIII of fresh frozen plasma and cryoprecipitate showed ten and five deviation data, respectively, the platelet content of apheresis platelet and platelets concentrate showed three and four deviations, respectively. Conclusion It's an effective way to ensure blood quality by trend analysis based on the results of key indexes of blood components, and actively find the cause and take corresponding measures in time.